| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
–Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event - |
| 27 Jul 2026 |
8-K: Results of Operations and Financial Condition; Other Events
As of June 30, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $138.3 million. This amount is unaudited and preliminary and is subject to the completion of financ... |
| 25 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Re: Amended and Restated Severance and Change of Control Letter Agreement |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 16, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) held its Annual Meeting of Stockholders (“Annual Meeting”). There were 115,511,771 shares of common stock, or approximately 62.59% of all outstanding shares, present in p... |
| 02 Jun 2026 |
8-K: Other Events
As previously reported, as of March 31, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) had $107.1 million of cash and cash equivalents. |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Tri... |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
–Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – |
| 11 Mar 2026 |
8-K: Other Events
As previously reported on January 8, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) received approximately $26.5 million in proceeds as of such date from the exercise of common stock warrants subsequent to December 31, 2025. Sinc... |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Other Events
As of December 31, 2025, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $71.8 million. This amount is unaudited and preliminary and is subject to the completion of fin... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
–Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML – |
| 27 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions he... |
| 03 Oct 2025 |
8-K: Entry into a Material Definitive Agreement
Reference is hereby made to that certain Sublease dated June 5, 2020, a Confirmation of Sublease Terms and Dates dated July 16, 2020, a First Amendment to Sublease dated December 6, 2021, a Second Amendment to Sublease dated December 11,... |
| 11 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
–Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, SELLAS Life Sciences Group, Inc. (the “Company”) held its Annual Meeting of Stockholders (“Annual Meeting”). There were 61,319,182 shares of common stock, or approximately 64.85% of all outstanding shares, present in pe... |
| 06 Jun 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by the SELLAS Life Sciences Group, Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements ... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
–Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based... |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition
–Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – |
| 29 Jan 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of January 28, 2025, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, i... |
Loading...